Publications

Detailed Information

Bioimaging of Nucleolin Aptamer-Containing 5-(N-benzylcarboxyamide)-2 `-deoxyuridine More Capable of Specific Binding to Targets in Cancer Cells

DC Field Value Language
dc.contributor.authorLee, Kyue Yim-
dc.contributor.authorKang, Hyungu-
dc.contributor.authorRyu, Sung Ho-
dc.contributor.authorLee, Dong Soo-
dc.contributor.authorKim, Soonhag-
dc.contributor.authorLee, Jung Hwan-
dc.date.accessioned2012-07-03T07:43:05Z-
dc.date.available2012-07-03T07:43:05Z-
dc.date.issued2010-
dc.identifier.citationJOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY; Vol. ; -ko_KR
dc.identifier.issn1110-7243-
dc.identifier.urihttps://hdl.handle.net/10371/78294-
dc.description.abstractChemically modified nucleotides have been developed and applied into SELEX procedure to find a novel type of aptamers to fit with targets of interest. In this study, we directly performed chemical modification of 5-(N-benzylcarboxyamide)-2`-deoxyuridine (called 5-BzdU) in the AS1411 aptamer, which binds to the nucleolin protein expressed in cancer cells. Forty-seven compounds of AS1411-containing Cy3-labeled 5-BzdU (called Cy3-(5-BzdU)-modified-AS1411) were synthesized by randomly substituting thymidines one to twelve in AS1411 with Cy3-labeled 5-BzdU. Both statistically quantified fluorescence measurements and confocal imaging analysis demonstrated at least three potential compounds of interest: number 12, 29 and 41 that significantly increased the targeting affinity to cancer cells but no significant activity from normal healthy cells. These results suggest that the position and number of substituents in AS1411 are critical parameters to improve the aptamer function. In this study, we demonstrated that chemical modification of the existing aptamers enhanced the binding and targeting affinity to targets of interest without additional SELEX procedures.ko_KR
dc.description.sponsorshipThis
work was supported by National R&D Program for Cancer
Control ofMinistry of Health &Welfare (0820320), National
Research Foundation of Korea (no. 20090084640), POSCO
Strategy R&D program (40003503.01), and a grant of the Korea Healthcare technology R&D Project, Ministry for
Health,Welfare & Family Affairs, South Korea (A085136).
ko_KR
dc.language.isoenko_KR
dc.publisherHINDAWI PUBLISHING CORPORATIONko_KR
dc.titleBioimaging of Nucleolin Aptamer-Containing 5-(N-benzylcarboxyamide)-2 `-deoxyuridine More Capable of Specific Binding to Targets in Cancer Cellsko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor이규임-
dc.contributor.AlternativeAuthor강현구-
dc.contributor.AlternativeAuthor류성호-
dc.contributor.AlternativeAuthor이동수-
dc.contributor.AlternativeAuthor이정환-
dc.contributor.AlternativeAuthor김순학-
dc.identifier.doi10.1155/2010/168306-
dc.citation.journaltitleJOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY-
dc.description.citedreferenceKo MH, 2009, SMALL, V5, P1207, DOI 10.1002/smll.200801580-
dc.description.citedreferenceRudge JS, 2007, P NATL ACAD SCI USA, V104, P18363, DOI 10.1073/pnas.0708865104-
dc.description.citedreferenceMhawech-Fauceglia P, 2007, HISTOPATHOLOGY, V50, P472, DOI 10.1111/j.1365-2559.2007.02635.x-
dc.description.citedreferenceHEIL JR, 2007-
dc.description.citedreferenceAnikeeva N, 2006, P NATL ACAD SCI USA, V103, P16846, DOI 10.1073/pnas.0607771103-
dc.description.citedreferenceChoi KH, 2006, MOL CANCER THER, V5, P2428, DOI 10.1158/1535-7163.MCT-05-0204-
dc.description.citedreferencePas J, 2006, INT J BIOCHEM CELL B, V38, P1594, DOI 10.1016/j.biocel.2006.03.017-
dc.description.citedreferenceZhang Z, 2005, CYTOTHERAPY, V7, P186, DOI 10.1080/14653240510027091-
dc.description.citedreferenceBurmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017-
dc.description.citedreferenceKato Y, 2005, NUCLEIC ACIDS RES, V33, P2942, DOI 10.1093/nar/gki578-
dc.description.citedreferenceDwarakanath S, 2004, BIOCHEM BIOPH RES CO, V325, P739, DOI 10.1016/j.bbrc.2004.10.099-
dc.description.citedreferenceVaught JD, 2004, J AM CHEM SOC, V126, P11231, DOI 10.1021/ja049009h-
dc.description.citedreferenceHerbst RS, 2004, INT J RADIAT ONCOL, V59, P21, DOI 10.1016/j.ijrobp.2003.11.041-
dc.description.citedreferenceChristian S, 2003, J CELL BIOL, V163, P871, DOI 10.1083/jcb.200304132-
dc.description.citedreferenceLato SM, 2002, NUCLEIC ACIDS RES, V30, P1401-
dc.description.citedreferenceMicklefield J, 2001, CURR MED CHEM, V8, P1157-
dc.description.citedreferenceBardeesy N, 1998, NUCLEIC ACIDS RES, V26, P1784-
dc.description.citedreferenceEaton BE, 1997, BIOORGAN MED CHEM, V5, P1087-
dc.description.citedreferenceEaton BE, 1997, CURR OPIN CHEM BIOL, V1, P10-
dc.description.citedreferenceCrooke ST, 1996, ANNU REV PHARMACOL, V36, P107-
dc.description.citedreferenceELLINGTON AD, 1990, NATURE, V346, P818-
dc.description.citedreferenceTUERK C, 1990, SCIENCE, V249, P505-
dc.description.tc3-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share